Physician profile
Paul N Smith
NPI 1861427692
$613.57
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $56.53 · 2021: $129 · 2022: $147.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $262.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.22 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $44.55 | 2019 | |
| Astellas Pharma US INC | $41.83 | 2019-2021 | |
| Ascend Therapeutics US, LLC | $37.48 | 2020-2022 | |
| Organon LLC | $31.10 | 2021 | |
| Ge Healthcare | $29.22 | 2020 | |
| Agile Therapeutics, INC. | $27.12 | 2021-2022 | |
| Exeltis, USA INC. | $14.72 | 2022 | |
| Intuitive Surgical, INC. | $13.49 | 2022 | |
| Covidien LP | $12.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.